Changes in cancer care are driving a demand for improved outcomes at greater efficiency and reduced costs. In this presentation, Dr. Julya Zuenkova describes a value-based approach in radiotherapy to use X-rays for operational efficacy. Learn how these treatments further advance patient adherence to treatment and improve skin cancer patients’ pathways for greater quality of life and shared decision making.
XBeam from Xstrahl Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance for Use in the U.S.
Xstrahl’s XBeam has received FDA 510(k) Clearance for Use in the U.S. The XBeam technology streamlines radiotherapy treatment planning and simplifies patient workflow for treating skin cancer, benign diseases, and palliative care. Explore how this innovation enhances orthovoltage superficial radiotherapy (SRT) and electronic brachytherapy (eBt). With XBeam, you can calculate, protocol and export treatment plans for Xstrahl treatments with Radiant Aura and all other Xstrahl medical devices in the U.S. and worldwide.
